Clal Insurance Enterprises Holdings Ltd Takes $141.28 Million Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Clal Insurance Enterprises Holdings Ltd bought a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,430,000 shares of the exchange traded fund’s stock, valued at approximately $141,284,000. SPDR S&P Biotech ETF accounts for approximately 1.2% of Clal Insurance Enterprises Holdings Ltd’s investment portfolio, making the stock its 23rd biggest holding. Clal Insurance Enterprises Holdings Ltd owned 1.88% of SPDR S&P Biotech ETF as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. raised its holdings in SPDR S&P Biotech ETF by 1.6% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,145,049 shares of the exchange traded fund’s stock worth $106,158,000 after purchasing an additional 18,202 shares during the period. Jane Street Group LLC raised its stake in shares of SPDR S&P Biotech ETF by 68.7% during the 1st quarter. Jane Street Group LLC now owns 961,082 shares of the exchange traded fund’s stock worth $91,197,000 after buying an additional 391,333 shares during the period. Mirae Asset Securities USA Inc. lifted its position in shares of SPDR S&P Biotech ETF by 50.0% during the 3rd quarter. Mirae Asset Securities USA Inc. now owns 900,000 shares of the exchange traded fund’s stock valued at $88,920,000 after buying an additional 300,000 shares in the last quarter. Employees Retirement System of Texas grew its stake in SPDR S&P Biotech ETF by 40.8% in the 2nd quarter. Employees Retirement System of Texas now owns 603,857 shares of the exchange traded fund’s stock valued at $55,984,000 after acquiring an additional 174,857 shares during the period. Finally, Main Management Fund Advisors LLC increased its holdings in SPDR S&P Biotech ETF by 8.3% in the 2nd quarter. Main Management Fund Advisors LLC now owns 598,200 shares of the exchange traded fund’s stock worth $55,459,000 after acquiring an additional 45,700 shares in the last quarter.

SPDR S&P Biotech ETF Stock Up 2.1 %

XBI opened at $96.24 on Friday. The firm’s fifty day simple moving average is $98.44 and its two-hundred day simple moving average is $96.23. SPDR S&P Biotech ETF has a 52-week low of $71.99 and a 52-week high of $105.47. The company has a market cap of $7.34 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.